BACKGROUND: Successful pregnancies require ®ne tuning of ®brinolytic activities in order to secure ®brin polymerization and stabilization of the placental basal plate as well as to prevent excess ®brin deposition in placental vessels and intervillous spaces. Fibrinolysis is tightly regulated by plasminogen activator inhibitor-1 (PAI-1). Endothelial PAI-1 synthesis is induced by angiotensin II, which is generated by angiotensin I-converting enzyme (ACE). METHODS: We studied the ACE deletion (D)/insertion (I) polymorphism and the PAI-1 4G/5G polymorphism in women with recurrent spontaneous miscarriages (RM). Both polymorphisms have been shown to be associated with ACE and PAI-1 expression levels respectively. A study group of 184 patients with a history of two or more consecutive unexplained spontaneous miscarriages was compared with a control group of 127 patients with uneventful term deliveries and no history of miscarriages. RESULTS: Our ®ndings show: (i) homozygosity for the D allele of the ACE gene, which results in elevated PAI-1 concentrations and hypo®brinolysis, is associated with an elevated risk of RM; (ii) the combination of the D/D genotype with two 4G alleles of the PAI-1 promoter, which further increases PAI-1 plasma levels, is signi®cantly more frequent in RM patients compared with controls. CONCLUSIONS: Based on these results, we recommend the incorporation of these two polymorphisms into the spectrum of thrombophilic mutations which should be analysed in individuals with recurrent spontaneous miscarriages. Patients homozygous for both the ACE D and PAI-1 4G alleles may bene®t from the application of low molecular weight heparin as early as possible in the pregnancy in order to prevent uteroplacental microthromboses.
Introduction
Recurrent spontaneous miscarriages (RM) affect up to 5% of fertile couples and, for many of them, the causes remain unexplained (Coulam et al., 1997) . Haemorheologic disposition plays a role and states of hypercoagulability due to mutations of procoagulatory factors such as coagulation factor V (FV) or prothrombin (FII) have been extensively investigated and associated with RM or severe pregnancy complications (Blumenfeld and Brenner, 1999; Kutteh et al., 1999; Kupferminc et al., 1999; Younis et al., 2000; Pihusch et al., 2001; Rai et al., 2002; Sarig et al., 2002) . Furthermore, hyperhomocysteinaemia seems to increase the risk of miscarriages. The most thoroughly investigated inherited risk factor for elevated homocysteine serum levels is homozygosity for the C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene (Girling and de Swiet, 1998; Nelen et al., 2000; Nelen, 2001) . However, the role played by the mutant MTHFR enzyme in pregnancy outcome is still not clear, and its effect might only be additive to other inherited or acquired thrombophilic factors (Sarig et al., 2002) .
Pregnancies appear to require an even balance of coagulation and ®brinolysis in order to avoid excess ®brin accumulation in placental vessels and intervillous spaces as well as to secure ®brin polymerization and stabilization of the placental basal plate (Preston et al., 1996; Buchholz and Thaler, 2003) . A successful implantation, on the other hand, needs endometrial vascular remodelling due to angiogenesis and vascular breakdown (Hickey and Fraser, 2000) . Adequate ®ne tuning of ®brinolysis is mandatory in order to prevent haemorrhage. For most tissues involved, ®brinolytic activity has been demonstrated (Lockwood, 2001; Smith et al., 2001; Chakraborty et al., 2002) . A variety of factors in¯uencing ®brinolysis has been studied. For instance, the ®brin-stabilizing factor (FXIII) has been shown to play an important role in placentation during the ®rst trimester of pregnancy (Kappelmayer et al., 1994) . De®ciency of FXIII with the resulting lack of ®brin stability and tendency towards hemorrhage as well as thrombosis is regarded as a risk factor for miscarriages (Anwar et al., 1999) . De®ciency of FXII, in contrast, impairs ®brinolysis by decreasing plasminogen activation, and this has repeatedly been associated with RM (Braulke et al., 1993; Ogasawara et al., 2001) . Minimal alterations in the ®brinolysis cascade leading to either hypo-or hyper®brinolysis are therefore suspected to interfere with placentation and early pregnancy. Several factors in¯uencing ®brinolysis, particularly the plasminogen activator inhibitors-1 and -2 (PAI-1 and PAI-2), have been shown to be up-regulated during implantation. They modify migration and invasive behaviour of extravillous trophoblast cells, and they also prevent additional haemorrhage during placentation (Feng et al., 2000; Lockwood, 2001) .
PAI-1 is a key regulating element in the ®brinolysis cascade. Recently, associations between polymorphisms in the PAI-1 and ACE genes and PAI-1 plasma levels have been established. Endothelial PAI-1 expression is modulated by a 4G/5G polymorphism in the PAI-1 promotor, 675 bp upstream from the start site of transcription. PAI-1 expression is also in¯uenced by angiotensin II plasma levels. Angiotensin II, a very potent vasoconstrictor, is generated by the angiotensin Iconverting enzyme (ACE), which is well known for its role in blood pressure regulation. ACE expression is associated with a deletion (D)/insertion (I) polymorphism in intron 16 of the ACE gene. Comparable to the PAI-1 4G allele, the ACE D allele leads to an increased PAI-1 expression, resulting in reduced ®brinolysis (Kim et al., 1997) .
These two genetic variations have been related to various vascular diseases such as myocardial infarction and deep vein thrombosis (Sartori et al., 1998 (Sartori et al., , 2000 Iacoviello et al., 1998; Seino et al., 1998; Gardemann et al., 1999; Lane and Grant, 2000) as well as to pregnancy-related disorders such as severe pre-eclampsia, pregnancy-induced hypertension, or serious pregnancy complications such as growth retardation and stillbirth (Zhu et al., 1998; Fatini et al., 2000; Glueck et al., 2000; Yamada et al., 2000) .
In order to evaluate whether ACE and PAI-1 expression levels affect the course of early pregnancies, we determined the prevalence of the ACE D/I and PAI-1 4G/5G polymorphisms in patients with RM.
Materials and methods
A total of 184 women who had experienced at least two unexplained consecutive spontaneous miscarriages before 25 weeks of gestation were studied after obtaining their informed consent. All patients were investigated b2 months after the last pregnancy to exclude the following established causes of RM: uterine anomalies (gynaecological examination, vaginal ultrasound, hysteroscopy), hypo-or hyperthyroidism (TSH), polycystic ovary syndrome [LH and FSH at cycle day 7, testosterone, dehydroepiandrosterone sulphate (DHEAS), vaginal ultrasound], antiphospholipid syndrome [IgG and IgM anticardiolipin antibodies, IgG and IgM anti-b2-glycoprotein antibodies, anti-nuclear antibodies, Lupus anticoagulant, activated partial thromboplastin time (aPTT)]. None of the patients had de®ciencies of antithrombin, protein C or protein S as determined by functional assays (Coumans et al., 1999) . Karyotyping was performed on both partners in order to exclude patients with chromosomal aberrations known to cause RM. The material from previous miscarriages was also karyotyped whenever possible. Miscarriages due to aneuploidy or other chromosomal imbalances were not counted as unexplained miscarriages (Quenby et al., 2002) . However, patients were evaluated for this study if they had at least two unexplained consecutive miscarriages. A total of 127 patients with one or more normal term deliveries after uneventful pregnancies and no history of miscarriages served as controls. All patients and controls were Caucasians.
To analyse the D/I polymorphism in intron 16 of the ACE gene and the ±675 4G/5G polymorphism in the promotor region of the PAI-1 gene, genomic DNA was extracted from leukocytes of patients and controls and ampli®ed by PCR using gene-speci®c primers. Each 50 ml reaction contained 10 mmol/l Tris±HCl, pH 8.3, 50 mmol/l KCl, 1.5 mmol/l MgCl 2 , 0.01% gelatin, 200 mmol/l of each dNTP, 20 mmol/l of each forward and reverse primer,~200 ng of high molecular weight DNA, and 1.25 IU Taq DNA Polymerase (Sigma±Aldrich). After denaturation at 95°C for 3 min, DNA fragments were ampli®ed for 35 cycles at 95°C for 30 s and at 72°C for 1 min (PAI-1), or for 40 cycles at 95°C for 20 s, at 56°C for 30 s, and at 72°C for 30 s (ACE). The PAI-1 4G/5G promoter genotype was determined according to Margaglione et al. (1994) by using a mutated oligonucleotide which contains a partial restriction site for the Bsl I enzyme (New England BioLabs), thus making it possible to identify the extra G base by restriction fragment length polymorphism analysis in 2% low melting point agarose gels (Gibco BRL Life Technologies). The ACE D/I genotype was characterized by the length of the PCR product, 190 bp in the case of the deletion and 490 bp in the presence of the insertion (Tiret et al., 1992) . Analyses of the thrombophilic FV Arg 506 ®Gln (factor V Leiden; FVL) and prothrombin G20210A mutations as well as of the MTHFR C677T substitution were performed as described elsewhere (Pihusch et al., 2001) .
For statistical analysis, results of the two groups were compared with the t-test or with the Pearson's c 2 -test for categorical variables. We performed a Kolmogorov±Smirnov test and the hypothesis that the data are normally distributed was not rejected. Association of RM with the ACE D/I and PAI-I 4G/5G polymorphisms and the MTHFR mutation was also tested with the Cochran±Armitage trend test.
Stepwise logistic regression analysis was performed with the patients and the controls as the dependent variable and the mutations/ polymorphisms in the factor V, prothrombin, MTHFR, PAI-1 and ACE genes as the explanatory variable. Statistical analyses were performed with the Statistical Package for Social Sciences (SPSS for Windows 9.0, SPSS Inc., USA) and the SAS statistical software (V8.1, SAS Institute Inc., USA). (Table I) . Heterozygosity for the FII mutation, by contrast, was signi®-cantly more prevalent among RM patients (4.9 versus 0.8%, P = 0.04), con®rming our previously published data (Pihusch et al., 2001) . Demographic data of the patients are shown in Table II in comparison with the 127 controls. RM patients were older, had fewer children, and (by de®nition) more miscarriages. The results concerning the ACE D/I polymorphism are given in Table III . The hypo®brinolytic D/D genotype was more prevalent in RM patients (32.1%) than in controls (23.6%; P = 0.11) although the difference was not signi®cant. The data regarding the PAI-1 promoter polymorphism are shown in Table IV . There was a tendency towards more 4G/4G carriers among RM patients (39.1%) than in controls (32.3%), but the difference was not signi®cant (P = 0.22).
As both polymorphisms in¯uence PAI-1 plasma levels and thereby plasmin and ®brin concentrations (Figure 1) , we also analysed combinatorial effects (Table V) . This revealed a signi®cant difference in the prevalence of the hypo®brinolytic combination of the PAI-1 4G/4G and ACE D/D genotypes, which was present in 13.6% of the RM patients, but only in 4.7% of the controls (P = 0.01). In contrast, individuals carrying the 4G/5G±D/I genotype (17.4% of the patients versus 28.3% of the controls; P = 0.02) appeared to have a lower risk of RM. The Cochran±Armitage trend test con®rmed the relationship between a combination of the PAI 4G/4G and ACE D/D genotypes and RM (P = 0.02). Logistic regression analysis also demonstrated a signi®cant in¯uence of these two factors combined (P = 0.03), while the FVL mutation and the MTHFR C677T genotype were not signi®cant variables. In addition, the impact of the FII mutation was veri®ed (P = 0.09; Table VI ). By stepwise logistic regression, the combination of the PAI-1 4G/4G and ACE D/D genotype was a signi®cant positive explanatory variable for miscarriages (P = 0.01) and a signi®cant independent risk factor for miscarriages with an odds ratio of 3.2.
Discussion
In our study, patients with unexplained RM had an increased prevalence of the ACE D/D genotype compared with the controls (32.1 versus 23.6%, P = 0.11), although this was not statistically signi®cant. Fatini et al. (2000) found a similar association of the D/D genotype with ®rst trimester miscarriages. Recently, they reported the ACE D/I polymorphism to be a stronger risk factor for RM than the two more wellestablished thrombophilic mutations FVL and FII G20210A as well as another ACE polymorphism. The association of D/D homozygosity with other pregnancy complications such as pregnancy-induced hypertension and pre-eclampsia, however, is controversial (Zhu et al., 1998; Morgan et al., 1999) . Glueck et al. (2000) stated that homozygosity for the 4G allele of the PAI-1 gene represents a serious risk for pregnancies, predisposing to prematurity, intrauterine growth retardation, miscarriage, and stillbirth. An earlier study in polycystic ovary syndrome (PCOS) patients with or without miscarriages also performed by Glueck et al. (1999) , in contrast, did not reveal a signi®cant difference with regard to the 4G/5G polymorphism of the PAI-1 gene. However, PCOS patients with at least one pregnancy were more likely to be heterozygous or homozygous carriers of the 4G allele than the healthy controls. Our ®ndings also con®rm a tendency of homozygous 4G allele carriers to be bound for miscarriages. None of these studies, however, investigated the cumulative risk associated with a combination of the two polymorphisms which are both known to in¯uence PAI-1 levels (Figure 1 ).
Both proteins affect the same downstream mechanism and combinatorial effects have been proposed to increase the incidence of diabetic macroangiopathy (Kimura et al., 1998) . Our study demonstrated that the combination of homozygosity for the PAI-1 4G and ACE D alleles was signi®cantly more prevalent among RM patients. Both the 4G allele and the D allele lead to an increased PAI-1 expression (Figure 1 ), which may result in hypo®brinolysis. Gris et al. (1997) postulated in a study of 500 patients that high PAI-1 levels may be a risk factor for RM. Excess ®brin accumulating in spiral arteries and within the intervillous space may well impede perfusion and prevent normal development of the pregnancy.
FVL and the MTHFR C677T mutation, in contrast, do not appear to signi®cantly predispose to ®rst or second trimester RM in our group of patients (Pihusch et al., 2001) . Using logistic regression analysis, we were also unable to ®nd an association between heterozygosity for FVL and homozygosity for the PAI-1 4G allele (P = 0.25). This is in con¯ict with data reported by Glueck et al. (2001) , showing a higher incidence of this combination in patients with severe pregnancy complications.
In conclusion, our results demonstrate that homozygosity for the ACE D allele is a risk factor for RM. Homozygosity for the ACE D and PAI-1 4G alleles additionally ampli®es the RM risk and this may very well be exerted by their common effect to increase PAI-1 expression. Analysis of these two polymorphisms should therefore be included in the routine work-up of patients with RM. The clinical implications of these data need to be addressed in a prospective study to answer the question whether or not double homozygous individuals should be treated with low molecular weight heparin. 
